Cathie Wood’s ARK ETFs have made their daily trades for Thursday, 24 April 2025, with a notable sell-off in Adaptive Biotechnologies Corp (NASDAQ: ADPT) and a purchase in Beam Therapeutics Inc (NASDAQ ...

The expansion is a good signal for an industry that slowed down, both in Chicago and nationwide, as interest rates rose and ...

NovoCure (NASDAQ: NVCR) published its first set of quarterly results for 2025, and they pleased more than a few investors.

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

STAT reporters chat about pharma tariffs, the latest recovery in biotech stocks, and disappointing data from a Bristol Myers ...

Pittsburgh biotech firms see potential benefits from upcoming tariffs and reshoring efforts, despite uncertainties in NIH ...

Portland-based biotech company Araceli Biosciences raised $11.2 million in new funding to fuel the expansion of its high-content imaging technology and AI-powered analysis used to speed drug discovery ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a $128 billion market cap. Renowned for its blockbuster drugs like Lipitor ...

STAT's Adam Feuerstein puts all his “Biotech Doom Loop” panic-mongering aside, as he embraces luminescent moonbeams and downy ...

Siren said proceeds will go toward investigational new drug (IND)-enabling animal studies and clinical-grade production of therapy. Upon FDA approval of an IND application, Siren plans to start on ...

Pelthos Therapeutics, a Durham-based wholly owned subsidiary of Ligand Pharmaceuticals (Nasdaq: LGND), is combining with ...

Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical stage tumor ...